Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07247188 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

Name: Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — clinical trial record (NCT07247188)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorSanofi

Started2026-01-20

View on ClinicalTrials.gov ↗

The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

Amendment history 1 change detected by DataLookout

2026-04-16

Trial sites expanded: 1 → 7 locations

Trial Details

NCT Number	NCT07247188
Lead Sponsor	Sanofi
Conditions	Sickle Cell Disease
Enrollment	100 participants
Start Date	2026-01-20
Primary Completion	2027-01-07 (estimated)
Study Completion	2027-01-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-15